SCIENCE
TSIT

SCIENCE

Next Generation Immunotherapy

We are developing T-sphaera with immune cell engaging function that has higher antigen binding ability,
and broader expandability compared to antibody treatments.

T-sphaera is a novel class of protein with higher antigen binding ability,
easy synthesis and broad expandability that can replace conventional antibodies.

Antigen Binding Ability Study

Superior target-binding ability compared to monoclonal antibody
& diverse target-binding capability

Immune Cell Engager

PD-L1 x TIGIT Bispecific T-sphaera

PD-L1 Antibody
Time: 24 h, Human cancer cell: 104 cells
PBMC: 105 cells, Cell ratio: 1:10, Concentration: 500 nM
Superior anti-cancer efficacy compared to monoclonal antibody